| 标题 |
MCL-1493: Fixed-Duration Outpatient Subcutaneous Mosunetuzumab + Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL) |
| 网址 | |
| DOI | |
| 其它 |
期刊:Clinical Lymphoma Myeloma and Leukemia 作者:Michael L. Wang; Manali Kamdar; Sarit Assouline; Nilanjan Ghosh; Seema Naik; et al 出版日期:2025-08-28 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)